A new expert consensus sets out a standardized framework for the surgical management of unilateral Wilms tumor (WT), the most common primary malignant renal tumor in children. Developed by the Oncology Surgery Group and Urology Surgery Group of the Pediatric Surgery Branch of the Chinese Medical Association, the consensus was published in World Journal of Pediatric Surgery on 17 June 2026 (DOI: 10.1136/wjps-2026-001204). It addresses decisions that still vary widely, including upfront surgery versus preoperative chemotherapy, biopsy, nephron-sparing surgery (NSS), lymph node sampling, renal vessel control, tumor thrombus, rupture, recurrence, metastases, minimally invasive surgery (MIS), horseshoe kidney, and special age groups.
WT outcomes have improved substantially through progress in molecular diagnosis, chemotherapy, radiotherapy, and surgery. Yet surgical management remains inconsistent, especially for large tumors, adjacent-organ invasion, intravascular extension, NSS, and lymph node biopsy. Surgeons also come from different specialties, which may contribute to variations in practice. Nonstandard procedures can cause tumor rupture, incomplete staging, recurrence, and iatrogenic progression. Computed tomography (CT) and magnetic resonance imaging (MRI) help identify risk features but have limited sensitivity for rupture, and lymph node size on imaging cannot reliably confirm metastasis. Preoperative imaging also cannot reliably detect every high-risk feature. Given these challenges, further research and consensus are needed to standardize surgical decision-making for unilateral WT.
Based on 17 clinical questions, the authors provide 34 recommendations on surgical timing, biopsy, incision, renal vessel control, lymph node sampling, tumor thrombus, rupture, recurrence, metastases, NSS, MIS, horseshoe kidney, special populations, and follow-up. The guidance targets pediatric surgeons, oncologists, urologists, and multidisciplinary teams. The consensus prioritizes complete local resection, accurate lymph node staging, and histological evaluation while minimizing complications. Immediate radical nephrectomy is recommended for resectable tumors; preoperative chemotherapy is advised for selected patients with high-risk or initially unresectable disease. Immediate surgery is discouraged in certain circumstances, including confirmed germline WT1 mutation, solitary kidney, severe anesthetic risk, or tumor thrombus above the hepatic veins.
Percutaneous biopsy is generally not recommended, but is suggested when renal origin is unclear, benign or non-WT disease is suspected, or in stage IV patients and those older than 10 years. A transverse abdominal or thoracoabdominal incision is preferred. Renal pedicle vessels should be ligated early when possible. Adequate lymph node sampling, ideally 6 to 10 nodes from renal hilar, aortocaval, paraaortic, aortic bifurcation, celiac trunk, superior mesenteric artery and iliac sites, improves staging and keeps the false-negative rate below 10%. The ureter should be divided distal to the iliac bifurcation. Adrenal and adjacent organs should be preserved unless directly invaded. Tumor thrombus management follows Daum classification, with neoadjuvant chemotherapy for thrombi above hepatic veins and multidisciplinary care for atrial extension. For recurrence, second-line chemotherapy is preferred; late isolated pulmonary or central nervous system lesions may be resected. NSS is not routine and requires strict criteria; MIS may be considered in selected cases at experienced centers, with conversion to open surgery when necessary.
The consensus is intended as a practical framework rather than a rigid protocol. The authors emphasize that complete resection and accurate staging remain non-negotiable, yet surgeons must balance oncologic control with renal preservation and avoid unnecessary harm. They stress that multidisciplinary discussion is essential for complex thrombus, recurrent disease, and unusual presentations, and that conversion from MIS to open surgery should be viewed as sound judgment rather than failure. The goal is safer surgery, better staging, and fewer avoidable recurrences. This consensus can help pediatric surgeons, oncologists, urologists, radiologists, and pathologists align care around common standards. Its recommendations support preoperative risk assessment, appropriate chemotherapy, adequate lymph node sampling, organ-preserving approaches when safe, and structured follow-up. In resource-limited settings, the framework may also guide referral and multidisciplinary planning. The authors call for future studies to refine patient selection for NSS and MIS, improve rupture prediction, standardize lymph node mapping, and clarify anticoagulation and radiotherapy decisions. Ultimately, the consensus aims to support more consistent, individualized care for children with unilateral WT, with potential to reduce tumor rupture, iatrogenic progression, recurrence, and unnecessary organ removal while preserving renal function and improving long-term outcomes.
